ArticleNature communications2016
Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 1 pooled it
10.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed, 1 synthesis or guideline pooled it, 183 citations in OpenAlex.
- A systematic review of the immuno-inflammatory dysfunction secondary to viral hemorrhagic fevers; Ebola and Lassa fever.PLoS neglected tropical diseases · 2025Pooled it
- Evaluation of candidate reference materials for the harmonization of Lassa fever serology.Emerging microbes & infections · 2026Article
- Lassa virus live tracking and lineage assignment: how nextstrain can enhance surveillance and public health in Africa and beyond.Emerging microbes & infections · 2026Article
- Sequence to structure insights into Lassa virus population-level biophysical properties and glycoprotein structure catalogue.Npj viruses · 2026Article
- B cell immunity to the Lassa virus glycoprotein is a correlate of vaccination-induced virus control in mice.Nature communications · 2026Article
- Site-1 protease mediated GPC processing is required for persistence of LCMV Clone 13.Npj viruses · 2026Article
- Development of a Conditional Replication System Using a Lassa Virus Glycoprotein Complex-Encoding Retroviral Vector for Isolating Resistant Variants to Inhibitors in BSL-2.International journal of molecular sciences · 2026Article
- High-throughput synthesis and specificity characterization of natively paired influenza hemagglutinin antibodies with oPoolScience translational medicine · 2025Article
- Infusion of neutralization into Lassa vaccine design.Trends in immunology · 2025Review
- Article
- Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials.EBioMedicine · 2025Article
- Lassa virus protein-protein interactions as mediators of Lassa fever pathogenesis.Virology journal · 2025Review
- Structure-guided design of a prefusion GPC trimer induces neutralizing responses against LASV.NPJ vaccines · 2025Article
- Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates.Emerging microbes & infections · 2024Article
- The DNA-based Lassa vaccine INO-4500 confers durable protective efficacy in cynomolgus macaques against lethal Lassa fever.Communications medicine · 2024Article
- Conformational ensemble-based framework enables rapid development of Lassa virus vaccine candidates.bioRxiv : the preprint server for biology · 2024Article
- Ebola Virus-Specific Neutralizing Antibody Persists at High Levels in Survivors 2 Years After Resolution of Disease in a Sierra Leonean Cohort.The Journal of infectious diseases · 2024Article
- Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses.Cell reports · 2024Article
- Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.Signal transduction and targeted therapy · 2024Review
- Deep mutational scanning reveals functional constraints and antibody-escape potential of Lassa virus glycoprotein complex.Immunity · 2024Article
71 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
50 authors at 12 institutions in 3 countries.
James E RobinsonSection of Infectious Disease, Department of Pediatrics, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, Louisiana 70112, USA.
Kathryn M HastieDepartment of Immunology and Microbial Science, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA.
Robert W CrossDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, 301 University Boulevard, Galveston, Texas 77555, USA.
Rachael E YenniDepartment of Microbiology and Immunology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, Louisiana 70112, USA.
Deborah H ElliottSection of Infectious Disease, Department of Pediatrics, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, Louisiana 70112, USA.
Julie A RouelleSection of Infectious Disease, Department of Pediatrics, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, Louisiana 70112, USA.
Chandrika B KannadkaSection of Infectious Disease, Department of Pediatrics, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, Louisiana 70112, USA.
Ashley A SmiraSection of Infectious Disease, Department of Pediatrics, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, Louisiana 70112, USA.
Courtney E GarrySection of Infectious Disease, Department of Pediatrics, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, Louisiana 70112, USA.
Benjamin T BradleySection of Infectious Disease, Department of Pediatrics, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, Louisiana 70112, USA.ORCID 0000-0002-8064-9314
Haini YuSection of Infectious Disease, Department of Pediatrics, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, Louisiana 70112, USA.
Jeffrey G ShafferDepartment of Biostatistics and Bioinformatics, Tulane School of Public Health and Tropical Medicine, New Orleans, Louisiana 70112, USA.
Matt L BoisenCorgenix, Inc., 11575 Main Street #400, Broomfield, Colorado 80020, USA.
Jessica N HartnettDepartment of Microbiology and Immunology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, Louisiana 70112, USA.
Michelle A ZandonattiDepartment of Immunology and Microbial Science, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA.
Megan M RowlandZalgen Labs, LLC, 20271 Goldenrod Lane, Suite 2083, Germantown, Maryland 20876, USA.
Megan L HeinrichZalgen Labs, LLC, 20271 Goldenrod Lane, Suite 2083, Germantown, Maryland 20876, USA.
Luis Martínez-SobridoDepartment of Microbiology and Immunology, University of Rochester, 601 Elmwood Avenue, Rochester, New York 14642, USA.
Benson ChengDepartment of Microbiology and Immunology, University of Rochester, 601 Elmwood Avenue, Rochester, New York 14642, USA.
Juan C de la TorreDepartment of Immunology and Microbial Science, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA.
Kristian G AndersenDepartment of Immunology and Microbial Science, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA.
Augustine GobaViral Hemorrhagic Fever Program, Kenema Government Hospital, 1 Combema Road, Kenema, Sierra Leone.
Mambu MomohViral Hemorrhagic Fever Program, Kenema Government Hospital, 1 Combema Road, Kenema, Sierra Leone.
Mohamed FullahViral Hemorrhagic Fever Program, Kenema Government Hospital, 1 Combema Road, Kenema, Sierra Leone.
Michael GbakieViral Hemorrhagic Fever Program, Kenema Government Hospital, 1 Combema Road, Kenema, Sierra Leone.
Lansana KannehViral Hemorrhagic Fever Program, Kenema Government Hospital, 1 Combema Road, Kenema, Sierra Leone.
Veronica J KoromaViral Hemorrhagic Fever Program, Kenema Government Hospital, 1 Combema Road, Kenema, Sierra Leone.
Richard FonnieViral Hemorrhagic Fever Program, Kenema Government Hospital, 1 Combema Road, Kenema, Sierra Leone.
Simbirie C JallohViral Hemorrhagic Fever Program, Kenema Government Hospital, 1 Combema Road, Kenema, Sierra Leone.
Brima KargboMinistry of Health and Sanitation, 4th Floor Youyi Building, Freetown, Sierra Leone.
Mohamed A VandiViral Hemorrhagic Fever Program, Kenema Government Hospital, 1 Combema Road, Kenema, Sierra Leone.
Momoh GbetuwaViral Hemorrhagic Fever Program, Kenema Government Hospital, 1 Combema Road, Kenema, Sierra Leone.
Odia IkponmwosaDepartment of Medicine, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Km. 87, Benin/Auchi Road, Irrua, Nigeria.
Danny A AsogunDepartment of Medicine, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Km. 87, Benin/Auchi Road, Irrua, Nigeria.
Peter O OkokhereDepartment of Medicine, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Km. 87, Benin/Auchi Road, Irrua, Nigeria.
Onikepe A FollarinDepartment of Medicine, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Km. 87, Benin/Auchi Road, Irrua, Nigeria.
John S SchieffelinSection of Infectious Disease, Department of Pediatrics, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, Louisiana 70112, USA.
Kelly R PittsCorgenix, Inc., 11575 Main Street #400, Broomfield, Colorado 80020, USA.
Joan B GeisbertDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, 301 University Boulevard, Galveston, Texas 77555, USA.
Peter C KulakoskiAutoimmune Technologies, LLC, 1010 Common St #1705, New Orleans, Louisiana 70112, USA.
Russell B WilsonAutoimmune Technologies, LLC, 1010 Common St #1705, New Orleans, Louisiana 70112, USA.
Christian T HappiDepartment of Medicine, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Km. 87, Benin/Auchi Road, Irrua, Nigeria.
Pardis C SabetiDepartment of Organismic and Evolutionary Biology, Center for Systems Biology, Harvard University, 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138, USA.
Sahr M GevaoDepartment of Medicine, University of Sierra Leone, Freetown, Sierra Leone.
S Humarr KhanViral Hemorrhagic Fever Program, Kenema Government Hospital, 1 Combema Road, Kenema, Sierra Leone.
Donald S GrantViral Hemorrhagic Fever Program, Kenema Government Hospital, 1 Combema Road, Kenema, Sierra Leone.
Thomas W GeisbertDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, 301 University Boulevard, Galveston, Texas 77555, USA.
Erica Ollmann SaphireDepartment of Immunology and Microbial Science, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA.
Luis M BrancoZalgen Labs, LLC, 20271 Goldenrod Lane, Suite 2083, Germantown, Maryland 20876, USA.
Robert F GarryDepartment of Microbiology and Immunology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, Louisiana 70112, USA.
Tulane University · USMinistry of Health and Sanitation · SLScripps Research Institute · USIrrua Specialist Teaching Hospital · NGThe University of Texas Medical Branch at Galveston · USUniversity of Sierra Leone · SLZalgen (United States) · USAutoimmune Technologies (United States) · USCorgenix (United States) · USRedeemer's University · NGUniversity of Rochester · USBroad Institute · US
Funding
Mechanistic Virology CoreU19AI109762 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI GARRY, ROBERT F · 2014 to 2018
$29.6MTulane Building Interdisciplinary Research Careers in Women's Health (BIRCWH)K12HD043451 · NICHD · TULANE UNIVERSITY OF LOUISIANA · PI KROUSEL-WOOD, MARIE · 2002 to 2023
$9.9MPreclinical development of recombinant antigen diagnostics for Lassa feverU01AI082119 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2009 to 2013
$6.7MMentoring Translational Researchers in LouisianaP20GM103501 · NIGMS · LSU HEALTH SCIENCES CENTER · PI OCHOA, AUGUSTO C. · 2012 to 2014
$6.3MAntibody immunotherapeutics for biodefense against Lassa virusR01AI104621 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2013 to 2017
$5.8MRecombinant antigen assays for Lassa and other arenaviruUC1AI067188 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2005 to 2005
$3.9MEBOLA VIRAL GLYCOPROTEINS: STRUCTURAL ANALYSISR01AI067927 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SAPHIRE, ERICA OLLMANN · 2006 to 2013
$3.6MImmunotherapeutics vs Ebola Sudan: Development, Structural & Functional AnalysisU01AI070530 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SAPHIRE, ERICA OLLMANN · 2006 to 2010
$3.5MRecombinant antigen diagnostics for filovirusesR44AI088843 · NIAID · ZALGEN LABS, LLC · PI BOISEN, MATTHEW L · 2014 to 2016
$3.0MSTRUCTURE DRIVEN ANALYSIS OF EBOLA VIRUS RECEPTOR BINDING SITER01AI081982 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SAPHIRE, ERICA OLLMANN · 2010 to 2014
$2.8MLate-stage development toward commercialization of multilineage point-of-care Lassa fever diagnosticsR44AI115754 · NIAID · ZALGEN LABS, LLC · PI BRANCO, LUIS MANUEL · 2015 to 2016
$1.9MHost and Microbial Genetic Determinants of Febrile Illness in West AfricaU01HG007480 · NHGRI · REDEEMER'S UNIVERSITY · PI HAPPI, CHRISTIAN T. · 2013 to 2016
$1.6MNHGRI NIH HHS U01 HG007480NIAID NIH HHS R01 AI067927NIAID NIH HHS R01 AI081982NIAID NIH HHS R01 AI104621NIAID NIH HHS R13 AI104216NIAID NIH HHS R21 AI121550NIAID NIH HHS R21 AI121840NIAID NIH HHS R43 AI088843NIAID NIH HHS R44 AI088843NIAID NIH HHS R44 AI115754NIAID NIH HHS U01 AI070530NIAID NIH HHS U01 AI082119NIAID NIH HHS U19 AI109762NIAID NIH HHS UC1 AI067188NICHD NIH HHS K12 HD043451NIGMS NIH HHS P20 GM103501
Abstract
Lassa fever is a severe multisystem disease that often has haemorrhagic manifestations. The epitopes of the Lassa virus (LASV) surface glycoproteins recognized by naturally infected human hosts have not been identified or characterized. Here we have cloned 113 human monoclonal antibodies (mAbs) specific for LASV glycoproteins from memory B cells of Lassa fever survivors from West Africa. One-half bind the GP2 fusion subunit, one-fourth recognize the GP1 receptor-binding subunit and the remaining fourth are specific for the assembled glycoprotein complex, requiring both GP1 and GP2 subunits for recognition. Notably, of the 16 mAbs that neutralize LASV, 13 require the assembled glycoprotein complex for binding, while the remaining 3 require GP1 only. Compared with non-neutralizing mAbs, neutralizing mAbs have higher binding affinities and greater divergence from germline progenitors. Some mAbs potently neutralize all four LASV lineages. These insights from LASV human mAb characterization will guide strategies for immunotherapeutic development and vaccine design.
Indexed as
Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntibody SpecificityAntigens, ViralArenavirusCross ReactionsEpitope MappingEpitopesHumansLassa FeverLassa virusModels, MolecularMutagenesis, Site-DirectedSequence DeletionViral Envelope ProteinsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntigens, ViralEpitopesglycoprotein gp1, lassa virusglycoprotein gp2, lassa virusViral Envelope Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.